SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, ...

Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing.

Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...

Research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Myriad Genetics in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that ...

Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...

New WWF-led research reveals that the vital benefits wildlife provides to people's everyday lives are vastly underrepresented ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

New research adds to our understanding of the function of the human genome. An international team of researchers has made ...